775 related articles for article (PubMed ID: 27741091)
1. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
2. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
[TBL] [Abstract][Full Text] [Related]
3. The impact of corticosteroid use during anti-PD1 treatment.
Pan EY; Merl MY; Lin K
J Oncol Pharm Pract; 2020 Jun; 26(4):814-822. PubMed ID: 31495293
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
5. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
7. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.
Queirolo P; Spagnolo F
Cancer Treat Rev; 2017 Sep; 59():71-78. PubMed ID: 28756306
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
Jacobsoone-Ulrich A; Jamme P; Alkeraye S; Dzwiniel V; Faure E; Templier C; Mortier L
Melanoma Res; 2016 Apr; 26(2):153-6. PubMed ID: 26636908
[TBL] [Abstract][Full Text] [Related]
9. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies.
Rodriguez-Ruiz ME; Rodriguez I; Barbes B; Mayorga L; Sanchez-Paulete AR; Ponz-Sarvise M; Pérez-Gracia JL; Melero I
Brachytherapy; 2017; 16(6):1246-1251. PubMed ID: 28838649
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
11. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
12. Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.
Damen PJJ; Suijkerbuijk KPM; VAN Lindert ASR; Eppinga WSC; El Sharouni SY; Verhoeff JJC
Anticancer Res; 2022 Oct; 42(10):4795-4804. PubMed ID: 36191990
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
16. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
Aboudaram A; Modesto A; Chaltiel L; Gomez-Roca C; Boulinguez S; Sibaud V; Delord JP; Chira C; Delannes M; Moyal E; Meyer N
Melanoma Res; 2017 Oct; 27(5):485-491. PubMed ID: 28858075
[TBL] [Abstract][Full Text] [Related]
17. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer.
Ji D; Song C; Li Y; Xia J; Wu Y; Jia J; Cui X; Yu S; Gu J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106387
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Maity A; Mick R; Huang AC; George SM; Farwell MD; Lukens JN; Berman AT; Mitchell TC; Bauml J; Schuchter LM; O'Hara M; Lin LL; Demichele A; Christodouleas JP; Haas NB; Patsch DM; Hahn SM; Minn AJ; Wherry EJ; Vonderheide RH
Br J Cancer; 2018 Nov; 119(10):1200-1207. PubMed ID: 30318516
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
20. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.
Chen D; Menon H; Verma V; Guo C; Ramapriyan R; Barsoumian H; Younes A; Hu Y; Wasley M; Cortez MA; Welsh J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31996395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
